Goldman Sachs’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-812,927
| Closed | -$2.47M | – | 6509 |
|
|
2024
Q4 | $2.47M | Sell |
812,927
-350,444
| -30% | -$1.53M | ﹤0.01% | 4097 |
|
|
2024
Q3 | $6.04M | Buy |
1,163,371
+229,753
| +25% | +$1.14M | ﹤0.01% | 3177 |
|
|
2024
Q2 | $2.4M | Buy |
933,618
+390,169
| +72% | +$1.33M | ﹤0.01% | 3793 |
|
|
2024
Q1 | $2.67M | Sell |
543,449
-240,179
| -31% | -$1.42M | ﹤0.01% | 3642 |
|
|
2023
Q4 | $6.89M | Sell |
783,628
-361,016
| -32% | -$2.96M | ﹤0.01% | 2868 |
|
|
2023
Q3 | $13.1M | Sell |
1,144,644
-596,258
| -34% | -$11.5M | ﹤0.01% | 2164 |
|
|
2023
Q2 | $44.1M | Buy |
1,740,902
+642,612
| +59% | +$20M | 0.01% | 1198 |
|
|
2023
Q1 | $35.4M | Sell |
1,098,290
-113,570
| -9% | -$3.54M | 0.01% | 1319 |
|
|
2022
Q4 | $22.4M | Buy |
1,211,860
+72,052
| +6% | +$1.65M | 0.01% | 1850 |
|
|
2022
Q3 | $30.8M | Buy |
1,139,808
+310,883
| +38% | +$6.31M | 0.01% | 1495 |
|
|
2022
Q2 | $11.5M | Buy |
828,925
+172,369
| +26% | +$2.65M | ﹤0.01% | 2385 |
|
|
2022
Q1 | $12.8M | Sell |
656,556
-149,476
| -19% | -$2.27M | ﹤0.01% | 2445 |
|
|
2021
Q4 | $13.2M | Buy |
806,032
+211,332
| +36% | +$3.52M | ﹤0.01% | 2513 |
|
|
2021
Q3 | $16.6M | Buy |
594,700
+129,264
| +28% | +$3.69M | ﹤0.01% | 2251 |
|
|
2021
Q2 | $13.8M | Buy |
465,436
+17,721
| +4% | +$511K | ﹤0.01% | 2390 |
|
|
2021
Q1 | $12.5M | Buy |
447,715
+43,589
| +11% | +$1.21M | ﹤0.01% | 2361 |
|
|
2020
Q4 | $11.5M | Sell |
404,126
-48,490
| -11% | -$1.26M | ﹤0.01% | 2348 |
|
|
2020
Q3 | $11.4M | Sell |
452,616
-108,259
| -19% | -$2.84M | ﹤0.01% | 2201 |
|
|
2020
Q2 | $13.7M | Sell |
560,875
-170,659
| -23% | -$3.37M | ﹤0.01% | 2005 |
|
|
2020
Q1 | $10.8M | Buy |
731,534
+623,626
| +578% | +$12.9M | ﹤0.01% | 2037 |
|
|
2019
Q4 | $1.75M | Buy |
107,908
+33,193
| +44% | +$515K | ﹤0.01% | 3742 |
|
|
2019
Q3 | $971K | Buy |
74,715
+21,030
| +39% | +$257K | ﹤0.01% | 4050 |
|
|
2019
Q2 | $696K | Sell |
53,685
-58,773
| -52% | -$741K | ﹤0.01% | 4223 |
|
|
2019
Q1 | $1.77M | Buy |
112,458
+72,996
| +185% | +$1.27M | ﹤0.01% | 3716 |
|
|
2018
Q4 | $794K | Sell |
39,462
-43,908
| -53% | -$967K | ﹤0.01% | 4099 |
|
|
2018
Q3 | $2.07M | Sell |
83,370
-52,872
| -39% | -$1.44M | ﹤0.01% | 3582 |
|
|
2018
Q2 | $3.74M | Buy |
136,242
+77,221
| +131% | +$2.32M | ﹤0.01% | 3168 |
|
|
2018
Q1 | $1.82M | Buy |
59,021
+32,475
| +122% | +$1.04M | ﹤0.01% | 3668 |
|
|
2017
Q4 | $949K | Sell |
26,546
-158,334
| -86% | -$4.55M | ﹤0.01% | 4364 |
|
|
2017
Q3 | $5.09M | Buy |
184,880
+5,223
| +3% | +$127K | ﹤0.01% | 3119 |
|
|
2017
Q2 | $4.74M | Sell |
179,657
-368,993
| -67% | -$8.23M | ﹤0.01% | 3102 |
|
|
2017
Q1 | $11.4M | Buy |
548,650
+141,400
| +35% | +$2.9M | ﹤0.01% | 2311 |
|
|
2016
Q4 | $8.43M | Sell |
407,250
-18,375
| -4% | -$308K | ﹤0.01% | 2588 |
|
|
2016
Q3 | $6.9M | Buy |
425,625
+446
| +0.1% | +$6.48K | ﹤0.01% | 2756 |
|
|
2016
Q2 | $5.78M | Buy |
425,179
+125,123
| +42% | +$2.21M | ﹤0.01% | 2739 |
|
|
2016
Q1 | $5.24M | Sell |
300,056
-15,770
| -5% | -$321K | ﹤0.01% | 2688 |
|
|
2015
Q4 | $10.8M | Sell |
315,826
-65,659
| -17% | -$2.28M | ﹤0.01% | 2197 |
|
|
2015
Q3 | $11.4M | Buy |
381,485
+71,547
| +23% | +$2.17M | ﹤0.01% | 2159 |
|
|
2015
Q2 | $9.91M | Sell |
309,938
-106,027
| -25% | -$2.73M | ﹤0.01% | 2340 |
|
|
2015
Q1 | $8.62M | Buy |
415,965
+13,210
| +3% | +$228K | ﹤0.01% | 2421 |
|
|
2014
Q4 | $6.82M | Sell |
402,755
-22,690
| -5% | -$396K | ﹤0.01% | 2688 |
|
|
2014
Q3 | $8.22M | Sell |
425,445
-14,257
| -3% | -$372K | ﹤0.01% | 2533 |
|
|
2014
Q2 | $14.9M | Buy |
439,702
+196,599
| +81% | +$6.16M | ﹤0.01% | 2036 |
|
|
2014
Q1 | $7.66M | Buy |
+243,103
| New | +$7.6M | ﹤0.01% | 2602 |
|
Other funds holding RVNC
Goldman Sachs's RVNC Position: Q1 2025 in Review
Goldman Sachs sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 812,927 shares — an estimated $2.47M sold.
Goldman Sachs first reported a position in RVNC in Q1 2014 and held it in 44 quarters. The position peaked at $44.1M in Q2 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Goldman Sachs reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Goldman Sachs sold 812,927 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $2.47M.
- Goldman Sachs first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 44 quarters.
- Goldman Sachs's Revance Therapeutics, Inc. position peaked at $44.1M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Goldman Sachs's 13F filing for Q1 2025, filed 9 May 2025.